Drugs / Cositecan
Cositecan
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00586560 | Feb 2007 → Jan 2011 | cancer | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00097903 | May 2004 → Oct 2011 | non-small cell lung carcinoma | BioNumerik Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00014521 | Jan 2002 → ? | central nervous system neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00358319 | Mar 2005 → Apr 2007 | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00054119 | Jan 2003 → Sep 2005 | ovarian carcinoma, primary peritoneal carcinoma | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00062491 | May 2002 → Jun 2003 | melanoma | BioNumerik Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00062478 | Oct 2001 → Aug 2002 | brain cancer | BioNumerik Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00010218 | Apr 2001 → Apr 2003 | lung cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00477282 | Aug 2007 → Jun 2013 | ovarian carcinoma | BioNumerik Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cositecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00054119 ↗ |
| Known as | BNP1350 | “Karenitecin also referred to as BNP1350” NCT00062478 ↗1“Karenitecin (BNP1350)” NCT00062491 ↗ |
| Known as | Karenitecin | “A Phase 1 Trial of Escalating Doses of Karenitecin Plus Cyclophosphamide Administered Intravenously Daily for 5 Consecutive Days in Pediatric Patients With Refractory or...” NCT00586560 ↗ |
| Known as | Karenitecin also referred to as BNP1350 | “Karenitecin also referred to as BNP1350” NCT00097903 ↗ |
| Known as | Karentecin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1997373 ↗ |
| Modality | Small molecule | — CHEMBL1997373 ↗ |
| Route | Intravenous | “Patients receive karenitecin IV over 60 minutes on days 1-5.” NCT00010218 ↗ |